Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

Clinical trial NCT07715565 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07715565
Sponsor: West China Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Renal Cell Carcinoma (Kidney Cancer)Immunotherapy Molecular Targeted Therapy

Start date: 2026-08-01
Primary completion: 2029-12-01
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.